TY - JOUR
T1 - Percutaneous radiofrequency ablation of hepatic colorectal metastases
T2 - Technique, indications, results, and new promises
AU - Lencioni, Riccardo
AU - Crocetti, Laura
AU - Cioni, Dania
AU - Della Pina, Clotilde
AU - Bartolozzi, Carlo
PY - 2004/11/1
Y1 - 2004/11/1
N2 - Surgical resection is the standard of care for colorectal metastases isolated to the liver. However, only 10-25% of the patients are eligible for resection because of extent and location of the disease in the liver or concurrent medical conditions. Image-guided radiofrequency (RF) ablation is a minimally invasive technique that is emerging as a viable alternate treatment of nonsurgical patients with limited hepatic metastatic disease. Several series have shown that RF ablation can result in complete tumor eradication in properly selected candidates and have provided indirect evidence that the treatment improves survival. In a recent multicenter trial including 423 patients, overall survival of RF-ablation treated patients reached 47% at 3 years and 24% at 5 years. RF ablation technology is undergoing continuous improvement, and its clinical application has been successfully expanded to the treatment of colorectal metastases to the lung. Randomized trials comparing RF ablation with either surgical resection or chemotherapy protocols, however, are still missing. In this article, we review technique, indications, clinical results, and future prospects of RF ablation in the therapeutic management of metastatic colorectal cancer patients.
AB - Surgical resection is the standard of care for colorectal metastases isolated to the liver. However, only 10-25% of the patients are eligible for resection because of extent and location of the disease in the liver or concurrent medical conditions. Image-guided radiofrequency (RF) ablation is a minimally invasive technique that is emerging as a viable alternate treatment of nonsurgical patients with limited hepatic metastatic disease. Several series have shown that RF ablation can result in complete tumor eradication in properly selected candidates and have provided indirect evidence that the treatment improves survival. In a recent multicenter trial including 423 patients, overall survival of RF-ablation treated patients reached 47% at 3 years and 24% at 5 years. RF ablation technology is undergoing continuous improvement, and its clinical application has been successfully expanded to the treatment of colorectal metastases to the lung. Randomized trials comparing RF ablation with either surgical resection or chemotherapy protocols, however, are still missing. In this article, we review technique, indications, clinical results, and future prospects of RF ablation in the therapeutic management of metastatic colorectal cancer patients.
KW - Colorectal cancer
KW - Liver metastases
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=7044234952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7044234952&partnerID=8YFLogxK
U2 - 10.1097/00004424-200411000-00007
DO - 10.1097/00004424-200411000-00007
M3 - Review article
C2 - 15486530
AN - SCOPUS:7044234952
VL - 39
SP - 689
EP - 697
JO - Investigative Radiology
JF - Investigative Radiology
SN - 0020-9996
IS - 11
ER -